Additional information as of 31 December 2024
Management report as of 31 December 2024
Notes to the individual financial report as of 31 December 2024
Individual financial report according to IFRS as of 31 December 2024
Notification from Donev Investments Holding AD in accordance with Regulation 596/2014 for receival of shares from the capital increase of Sopharma AD
Sales revenues for December 2024
Sofia, Bulgaria January 20, 2025 – According to the requirements of Art. 100t of the Law on Public Offering of Securities (LPOS), “Sopharma” AD (SFA: “Bulgarian Stock Exchange” AD, SPH: Warsaw Stock Exchange) notifies, that for December 2024 the Company recorded an increase in sales of 55% compared to the same month of the previous year, incl. 29% increase in domestic sales and 77% increase in export sales.
For the period from the beginning of 2024, the Company recorded a decrease in sales of 5%, incl. 5% increase of domestic sales and 11% decrease in export sales.
Results of conditional capital increase of Sopharma AD by exercising warrants from an issue with ISIN BG9200001212
Sofia, Bulgaria, January 15, 2025 – According to the requirements of art. 100t of LPOS, “Sopharma” AD (SFA: Bulgarian Stock Exchange, SPH: Warsaw Stock Exchange) notifies that in pursuance of a decision of the Board of Directors of SOPHARMA AD from October 14, 2024 and based on art. 195 and art. 196 of the Commercial Law (CL), art. 113, para. 2, item 2 of Law on public offering of securities (LPOS) and art.
Notification from Ognian Donev in accordance with Regulation 596/2014 for transactions with shares of Sopharma AD as of 27 December 2024
Notification from Ognian Donev in accordance with Regulation 596/2014 for transactions with shares of Sopharma AD as of 27 December 2024
Notification from Donev Investments Holding AD in accordance with Regulation 596/2014 for transactions with shares of Sopharma AD as of 27 December 2024
Notification from Donev Investments Holding AD in accordance with Regulation 596/2014 for transactions with shares of Sopharma AD as of 27 December 2024